Oral Lipid-Based Formulations: Unlocking Value in Early-Stage Pharmaceutical Development
Abstract: Pharmaceutical innovators face growing pressure to overcome solubility, permeability, and bioavailability challenges, especially for complex, poorly soluble molecules. This executive summary explores how oral lipid-based formulations (LBFs), particularly when combined with advanced encapsulation and predictive modeling, can dramatically accelerate development timelines and improve clinical outcomes.
Gain insights from leading industry and academic experts on how LBFs optimize drug delivery by leveraging the body’s natural digestive mechanisms, enabling both small and large molecule delivery. Discover why LBFs are ideal for early-phase development, how they synergize with amorphous solid dispersions (ASDs), and how Catalent’s integrated softgel technologies such as OptiGel® and OptiGel DR® are unlocking new value in formulation science.
Whether you’re seeking improved oral bioavailability, better GI stability, or scalable manufacturing solutions, this summary outlines actionable strategies to reduce risk, speed time-to-clinic, and improve patient compliance.